Delivery Order SPE2DR25D3014-SPE2DR26FP1JW
- Not listed
- The Defense Logistics Agency awarded a delivery order to AmerisourceBergen Drug Corp for Prograf 1 mg capsules (100-count units) on November 5, 2025, with a ceiling value of $5,083.18. This non-competitive, firm fixed-price delivery order is expected to be completed by November 6, 2025, and will be performed at AmerisourceBergen's corporate office location in Conshohocken, Pennsylvania. The award represents a child contract under the company's larger Indefinite Delivery Contract (IDC) with DLA...
- The Defense Logistics Agency awarded AmerisourceBergen Drug Corp a delivery order valued at $4,663.57 on October 20, 2025, for the supply of Prograf 0.5 mg capsules (100-count units). This is a firm fixed-price delivery order with no set-aside designation, indicating competitive award through open competition. The contract will be performed at AmerisourceBergen's corporate office location in Conshohocken, Pennsylvania, with an ultimate completion date of October 21, 2025. This delivery order...
- The Defense Logistics Agency awarded a delivery order to AmerisourceBergen Drug Corp for $1,423.23 to supply Prograf 1 mg capsules (100-count units) with a firm fixed price structure. This non-set-aside competitive award was executed on November 18, 2025, with an ultimate completion date of November 19, 2025, and will be performed at AmerisourceBergen's corporate office location in Conshohocken, Pennsylvania. Prograf (tacrolimus) is an immunosuppressant medication commonly used in transplant...
- The Defense Logistics Agency awarded a delivery order to AmerisourceBergen Drug Corp on November 4, 2025, for the supply of Prograf 1 mg capsules (100-count) with a ceiling value of $9,453.72. This firm fixed-price contract, with an ultimate completion date of November 5, 2025, represents a child delivery order under AmerisourceBergen's larger Indefinite Delivery Contract with DLA Troop Support Medical (SPE2DX), valued at $999,999,999.00 and extending through December 2026. The award was...
- The Defense Logistics Agency (DLA) awarded a delivery order to AmerisourceBergen Drug Corp on October 30, 2025, for the supply of Prograf 1 mg capsules in quantities of 100 units. This contract, which is a child order under AmerisourceBergen's larger indefinite delivery contract with DLA Troop Support Medical (SPE2DX, valued at $999.9 million through December 2026), carries a ceiling value of $2,747.52 and employs firm fixed-price pricing with no set-aside designation. The product will be...
- The Defense Logistics Agency awarded a delivery order valued at $1,831.68 to AmerisourceBergen Drug Corp for Prograf 1 mg capsules (100-count units) on December 1, 2025, with a completion date of December 2, 2025. This competitive award, which carries no set-aside designation, represents a firm fixed-price transaction for pharmaceutical supply to support federal medical procurement needs. AmerisourceBergen Drug Corp, a major pharmaceutical distributor headquartered in Conshohocken, Pennsylvania,...
- The Defense Logistics Agency awarded a delivery order valued at $27,638.41 to AmerisourceBergen Drug Corp for the supply of Prograf 1 mg capsules (100-count units) with a completion date of August 25, 2025. This is a firm fixed-price delivery order under a non-set-aside competition, with performance to be executed at the contractor's Conshohocken, Pennsylvania facility. AmerisourceBergen Drug Corp, a major pharmaceutical distributor and critical vendor for federal medical procurement, fulfills...
- The Defense Logistics Agency awarded a $5,179.38 delivery order to AmerisourceBergen Drug Corp for 100 capsules of Prograf 1 mg on November 18, 2025, with completion scheduled for November 19, 2025. This non-set-aside, competitively awarded contract utilizes firm fixed price pricing and represents a child order under AmerisourceBergen's larger pharmaceutical supply vehicle with DLA. The pharmaceutical product will be delivered to the company's facility in Conshohocken, Pennsylvania. This...
- The Defense Logistics Agency awarded a delivery order to AmerisourceBergen Drug Corp for the supply of Prograf 1 mg capsules (100-count units) with a ceiling value of $1,303.59. This firm fixed-price delivery order, awarded on September 23, 2025, with an ultimate completion date of September 24, 2025, represents a direct fulfillment from AmerisourceBergen's existing contract vehicle. The award was made through open competition with no set-aside designation, and performance will take place at the...
- The Defense Logistics Agency awarded a delivery order valued at $41,735.37 to AmerisourceBergen Drug Corp for the supply of Prograf 5 mg capsules (100 count units) under a firm fixed price contract. The award was made on September 17, 2025, with an ultimate completion date of September 18, 2025, and will be performed at the contractor's corporate office location in Conshohocken, Pennsylvania. This non-set-aside award represents a competitively awarded transaction for a critical pharmaceutical...
- SPE2DR25D3014Indefinite Delivery Contract
- SPE2DR25D3014-SPE2DR26FP1JWDelivery Order
The Defense Logistics Agency awarded a delivery order to AmerisourceBergen Drug Corp for Prograf 1 mg capsules (100-count) valued at $2,767.42, with an ultimate completion date of December 19, 2025. This is a firm fixed-price delivery order with no set-aside designation, issued competitively to the pharmaceutical distributor's Conshohocken, Pennsylvania location. The award represents a child contract under AmerisourceBergen's larger Indefinite Delivery Contract with DLA Troop Support Medical (SPE2DX), a $999.99 billion prime vendor agreement running through December 2026 that enables global pharmaceutical supply support to military healthcare systems worldwide. AmerisourceBergen Drug Corp, a major pharmaceutical distributor and healthcare solutions provider headquartered in Pennsylvania, holds a significant position within the Defense Logistics Agency's medical supply chain. This particular delivery order for Prograf—an immunosuppressant medication commonly used in transplant and autoimmune disease management—demonstrates the company's role in fulfilling critical pharmaceutical needs for the Defense Health Agency and other federal healthcare systems. The non-set-aside, competitively awarded contract reflects AmerisourceBergen's established capability to meet federal procurement requirements and its extensive portfolio of pharmaceutical products spanning multiple therapeutic domains.
Mod # | Description | ReasonForModification | Federal Obligation | Date |
|---|---|---|---|---|
| Not listed | Not listed | $2.8k | 12/17/25 |